Replacement of valsartan and candesartan by telmisartan in hypertenitive patients with type 2 diabetes

被引：87

作者：

Miura, Y ^{[1
]}

Yamamoto, N ^{[1
]}

Tsunekawa, S ^{[1
]}

Taguchi, S ^{[1
]}

Eguchi, Y ^{[1
]}

Ozaki, N ^{[1
]}

Oiso, Y ^{[1
]}

机构：

[1] Nagoya Univ, Sch Med, Dept Endocrinol & Diabet, Showa Ku, Nagoya, Aichi 4558550, Japan

来源：

DIABETES CARE | 2005年 / 28卷 / 03期

关键词：

D O I：

10.2337/diacare.28.3.757

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：757 / 758

页数：2

共 10 条

[1] Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity [J].

Benson, SC ;

Pershadsingh, HA ;

Ho, CI ;

Chittiboyina, A ;

Desai, P ;

Pravenec, M ;

Qi, NN ;

Wang, JM ;

Avery, MA ;

Kurtz, TW .

HYPERTENSION, 2004, 43 (05) :993-1002

[2] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[3] An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes [J].

Fujimoto, M ;

Masuzaki, H ;

Tanaka, T ;

Yasue, S ;

Tomita, T ;

Okazawa, K ;

Fujikura, J ;

Chusho, H ;

Ebihara, K ;

Hayashi, T ;

Hosoda, K ;

Nakao, K .

FEBS LETTERS, 2004, 576 (03) :492-497

[4] Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats [J].

Henriksen, EJ ;

Jacob, S ;

Kinnick, TR ;

Teachey, MK ;

Krekler, M .

HYPERTENSION, 2001, 38 (04) :884-890

[5] Possible beneficial effect of telmisartan on glycemic control in diabetic subjects [J].

Honjo, S ;

Nichi, Y ;

Wada, Y ;

Hamamoto, Y ;

Koshiyama, H .

DIABETES CARE, 2005, 28 (02) :498-498

[6] Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].

Julius, S ;

Kjeldsen, SE ;

Weber, M ;

Brunner, HR ;

Ekman, S ;

Hansson, L ;

Hua, TS ;

Laragh, J ;

McInnes, GT ;

Mitchell, L ;

Plat, F ;

Schork, A ;

Smith, B ;

Zanchetti, A .

LANCET, 2004, 363 (9426) :2022-2031

[7] Insulin-sensitizing effects of telmisartan [J].

Pershadsingh, HA ;

Kurtz, TW .

DIABETES CARE, 2004, 27 (04) :1015-1015

[8] Mechanisms of disease - Atherosclerosis - An inflammatory disease [J].

Ross, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) :115-126

[9] Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-α activity [J].

Schupp, M ;

Janke, J ;

Clasen, R ;

Unger, T ;

Kintscher, U .

CIRCULATION, 2004, 109 (17) :2054-2057

[10] The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity [J].

Yamauchi, T ;

Kamon, J ;

Waki, H ;

Terauchi, Y ;

Kubota, N ;

Hara, K ;

Mori, Y ;

Ide, T ;

Murakami, K ;

Tsuboyama-Kasaoka, N ;

Ezaki, O ;

Akanuma, Y ;

Gavrilova, O ;

Vinson, C ;

Reitman, ML ;

Kagechika, H ;

Shudo, K ;

Yoda, M ;

Nakano, Y ;

Tobe, K ;

Nagai, R ;

Kimura, S ;

Tomita, M ;

Froguel, P ;

Kadowaki, T .

NATURE MEDICINE, 2001, 7 (08) :941-946

← 1 →